← Leaderboards
Yousif H Matloub
University Of Wisconsin Madison
$547,398
Attributed
$547,398
Total exposure
26
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $202.4K · FY2005–07$250K$187.5K$125K$62.5K$0
'05
'06
'07
Funding mix
By agency
NIH$547,398 · 26
By mechanism
M01$547,398 · 26
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- James A Stewart$6,121,809
- Paul M Sondel$16,210,986
- Robert T Striker$387,957
- George Wilding$32,976,854
- Diane M Puccetti$719,707
Others in their field
Top investigators on “Combination Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$152,507,709
- Philip J Disaia · University Of California Irvine$115,767,092
- Norman Wolmark · Nsabp Foundation, Inc.$63,073,711
- Richard L Schilsky · University Of Chicago$54,853,416
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
Research focus
Combination ChemotherapyClinical TrialsSourceResourcesRandomizedHuman SubjectPatient Oriented ResearchInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelHuman Therapy EvaluationFundingGrantChemotherapyChemotherapy-Oncologic ProcedureUnited States National Institutes Of HealthNeoplasm /Cancer ChemotherapyDrug UsageClinical ResearchNational Cancer InstituteDatabasesClinical Trials, Phase IiiPhysician Data QueryKillings
Grant awards (33)
STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA$15,227
M01 · FY2007 · RR · contact PI
HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA$4,579
M01 · FY2007 · RR · contact PI
CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE$2,970
M01 · FY2007 · RR · contact PI
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL$2,404
M01 · FY2007 · RR · contact PI
COMPARISON OF CHEMOTHERAPY REGIMENS IN CHILDREN WITH RHABDOMYOSARCOMA$2,378
M01 · FY2007 · RR · contact PI
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS$1,959
M01 · FY2007 · RR · contact PI
CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA$74
M01 · FY2007 · RR · contact PI
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS$50,485
M01 · FY2006 · RR · contact PI
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL$36,740
M01 · FY2006 · RR · contact PI
STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA$36,429
M01 · FY2006 · RR · contact PI
HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA$30,750
M01 · FY2006 · RR · contact PI
CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA$26,515
M01 · FY2006 · RR · contact PI
CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE$16,228
M01 · FY2006 · RR · contact PI
TREATMENT FOR INFANTS AND CHILDREN WITH INTERMEDIATE-RISK NEUROBLASTOMA$2,979
M01 · FY2006 · RR · contact PI
PRIMARY SURGICAL THERAPY FOR BIOLOGICALLY DEFINED LOW-RISK NEUROBLASTOMA$1,645
M01 · FY2006 · RR · contact PI
PURGED VS UNPURGED PBSC TRANSPLANT FOLLOWING DOSE INTENSIVE INDUCTION THERAPY$667
M01 · FY2006 · RR · contact PI
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL$65,992
M01 · FY2005 · RR
CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA$21,367
M01 · FY2005 · RR
PURGED VS UNPURGED PBSC TRANSPLANT FOLLOWING DOSE INTENSIVE INDUCTION THERAPY$13,146
M01 · FY2005 · RR
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS$6,217
M01 · FY2005 · RR
TREATMENT FOR INFANTS AND CHILDREN WITH INTERMEDIATE-RISK NEUROBLASTOMA$6,124
M01 · FY2005 · RR
PRIMARY SURGICAL THERAPY FOR BIOLOGICALLY DEFINED LOW-RISK NEUROBLASTOMA$3,970
M01 · FY2005 · RR
PHASE III STUDY IN CHILDREN WITH UNTREATED AML OR MDS$1,666
M01 · FY2005 · RR
ACTINOMYCIN D AND VCR WITH OR WITHOUT CTX AND XRT FOR RMS OR SARCOMA$1,236
M01 · FY2005 · RR
CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE$806
M01 · FY2005 · RR
CH1418 IN HIGH-RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND ASCT$487
M01 · FY2005 · RR
Comparison of Different Combination Chemotherapy Regimens in Children with ALL$108,561
M01 · FY2004 · RR
ch14.18 in High-Risk Neuroblastoma Following Myeloablative Therapy and ASCT$46,625
M01 · FY2004 · RR
Phase III Study in Children with Untreated AML or MDS$23,746
M01 · FY2004 · RR
Actinomycin D and VCR with or without CTX and XRT for RMS or Sarcoma$9,706
M01 · FY2004 · RR
Randomized Study of VAC vs. VAC Alternating with VTC in Intermediate Risk RMS$2,484
M01 · FY2004 · RR
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma$1,907
M01 · FY2004 · RR
Irinotecan and Cisplatin in Children with Refractory Solid Tumors$1,329
M01 · FY2004 · RR